Core Insights - Chemomab Therapeutics has announced positive results from its Phase 2 SPRING trial for nebokitug, a treatment for primary sclerosing cholangitis (PSC), which supports advancing to a Phase 3 registration trial [1][3] Group 1: Trial Results - The Phase 2 SPRING trial demonstrated that nebokitug was generally safe and well tolerated for up to 48 weeks, with significant improvements in biomarkers for inflammation and fibrosis, particularly at the 20 mg/kg dose [2][7] - In patients with moderate/advanced fibrosis, nebokitug showed a dose-dependent biological activity, with about half of the study population falling into this category [7][10] - The trial included 76 patients across 33 sites in the US, UK, Germany, Spain, and Israel, with over 90% of eligible patients opting for an open-label extension study [6] Group 2: Mechanism of Action - Nebokitug is a humanized IgG1 anti-CCL24 monoclonal antibody that targets CCL24, which is associated with inflammatory and fibrotic processes in PSC [5][12] - Elevated CCL24 levels have been linked to disease severity in PSC, and inhibiting CCL24 with nebokitug has shown therapeutic benefits in experimental models [5][12] Group 3: Future Prospects - Based on the positive data from the SPRING trial, Chemomab is preparing to initiate a Phase 3 trial, which will focus on a clinical event primary endpoint to streamline the regulatory approval process [12] - Nebokitug has received Orphan Drug and Fast Track designations from the FDA, indicating its potential significance in treating PSC [12]

Core Insights - Chemomab Therapeutics Ltd. is a clinical stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases with significant unmet medical needs [4] Group 1: Company Overview - Chemomab is developing nebokitug, a first-in-class dual activity monoclonal antibody targeting the soluble protein CCL24, which plays a role in fibrosis and inflammation [4] - Nebokitug has shown a favorable safety profile and has been well-tolerated in clinical and preclinical studies, with potential applications in multiple severe fibro-inflammatory diseases [4] - The company has reported positive results from five clinical trials of nebokitug, particularly from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC) [4] - Chemomab is preparing to initiate a Phase 3 trial for nebokitug in PSC, which is designed as a single pivotal trial with a clear pathway to regulatory approval [4] - Nebokitug has received Orphan Drug and Fast Track designations from the FDA and EMA for the treatment of PSC [4] Group 2: Upcoming Events - Co-founder and CEO Adi Mor will participate in Oppenheimer's Movers in Rare Disease Summit on December 11, 2025, in New York City [1][3] - Dr. Mor will present a corporate overview and will be available for one-on-one meetings with registered attendees during the summit [2][3]

Core Insights - Chemomab Therapeutics is advancing its preparations for the Phase 3 trial of nebokitug for primary sclerosing cholangitis (PSC), with positive feedback from both the FDA and EMA indicating that a single registration trial will suffice for approval [3][10] - The Phase 2 SPRING trial data presented at AASLD 2025 showed favorable safety and consistent improvements in key biomarkers for PSC patients treated with nebokitug for up to 48 weeks [4][10] - The company has multiple partnering options to support the Phase 3 program and expects its cash runway to last through the end of Q4 2026 [1][8] Regulatory Developments - The FDA and EMA have aligned on the trial design, allowing a composite of clinically relevant events as the study endpoint, which streamlines the pathway to potential regulatory approval [3][10] - The support from the PSC community at the AASLD 2025 conference indicates growing interest and recognition of nebokitug's potential as a disease-modifying therapy [3][4] Clinical Data - Data from the Phase 2 SPRING trial highlighted nebokitug's positive effects on inflammatory and fibrotic biomarkers, confirming its good safety profile and disease-modifying potential [4][10] - New insights into nebokitug's mechanism of action were presented, emphasizing its role in halting or slowing disease progression in PSC [4][10] Financial Performance - As of September 30, 2025, Chemomab reported cash and cash equivalents of $10.2 million, an increase from $9.5 million as of June 30, 2025, and $14.2 million as of December 31, 2024 [8] - Research and Development expenses decreased to approximately $1 million in Q3 2025 from $2.8 million in Q3 2024, primarily due to the conclusion of the Phase 2 SPRING trial activities [8][13] - The net loss for Q3 2025 was $1.7 million, a reduction from a net loss of $3.5 million in Q3 2024, reflecting improved financial management [8][13]

Core Insights - Chemomab Therapeutics announced new clinical data from the Phase 2 SPRING trial of nebokitug for primary sclerosing cholangitis (PSC), showing favorable safety and consistent improvements in key biomarkers over 48 weeks of treatment [1][2] Group 1: Clinical Trial Results - The open-label extension (OLE) of the SPRING trial demonstrated that nebokitug was well-tolerated and maintained its anti-inflammatory and anti-fibrotic effects for up to 48 weeks, with significant improvements in biomarkers such as ELF score and liver stiffness [2][3] - Out of 54 eligible patients who completed the initial 15-week double-blind portion, 50 chose to continue in the OLE, receiving up to 33 additional weeks of treatment [3] - The results support the evaluation of nebokitug at a dosage of 20 mg/kg in a Phase 3 trial for PSC patients [3] Group 2: Mechanism of Action - Nebokitug targets macrophage-mediated mechanisms in PSC, showing dose-dependent reductions in serum macrophage-related proteins, particularly in patients with moderate to advanced disease [4][5] - The treatment led to increased expression of macrophage stimulating protein 1 (MST1), which is functionally impaired in PSC patients due to a genetic variant [6] - Changes in MST1 levels were associated with improvements in liver stiffness measurements, indicating its potential as a biomarker for nebokitug's activity [6] Group 3: Future Directions - Chemomab is preparing for a Phase 3 trial based on positive data from the Phase 2 SPRING trial, with a focus on a clinical event primary endpoint to streamline regulatory approval [10] - Nebokitug has received FDA and EMA Orphan Drug designations and FDA Fast Track designation for PSC treatment, highlighting its potential in addressing unmet medical needs [10]

Core Insights - Three stocks are highlighted with strong momentum characteristics and a buy rank as of October 23, including Par Pacific Holdings, Chemomab Therapeutics, and Guess, Inc. [1][2][3] Group 1: Par Pacific Holdings, Inc. (PARR) - Par Pacific Holdings has a Zacks Rank 1 and saw its earnings estimate increase by 100.6% over the last 60 days [1] - The company's shares increased by 17.5% over the last three months, outperforming the S&P 500, which advanced by 6% [1] - Par Pacific possesses a Momentum Score of A [1] Group 2: Chemomab Therapeutics Ltd. (CMMB) - Chemomab Therapeutics also holds a Zacks Rank 1, with a 70% increase in its earnings estimate over the last 60 days [2] - The stock gained 18.9% in the last month, significantly outperforming the S&P 500's 1.7% increase [2] - Chemomab has a Momentum Score of A [2] Group 3: Guess?, Inc. (GES) - Guess has a Zacks Rank 1, with an 8.1% increase in its earnings estimate over the last 60 days [3] - The company's shares rose by 27.4% over the last three months, again outperforming the S&P 500's 6% advance [3] - Guess possesses a Momentum Score of B [3]

Core Insights - Biotech stocks experienced significant gains in after-hours trading on October 22, 2023, primarily driven by Ventyx Biosciences' positive Phase 2 data, which led to an 88% surge in its stock price [1][2]. Company Performance - Ventyx Biosciences Inc. (VTYX) saw its shares increase by over 88% following the announcement of positive results from its Phase 2 study of VTX3232 for patients with obesity and cardiovascular risk factors [2]. - Medpace Holdings, Inc. (MEDP) reported better-than-expected Q3 results, resulting in an over 18% increase in its stock price during after-hours trading [2]. - Inhibrx Biosciences Inc. (INBX) shares rose over 10% to $34.98 after announcing a live webcast presentation to discuss topline results from the ChonDRAgon study [3]. - SCYNEXIS Inc. (SCYX) shares increased by over 11% to $0.87 [4]. - Acumen Pharmaceuticals Inc. (ABOS) experienced a notable rise of over 24.9% to $2.31 [4]. - Rani Therapeutics Holdings Inc. (RANI) shares were up over 9% at $2.64 [4]. - iBio Inc. (IBIO) shares increased by over 7% to $1.50 [4]. - Chemomab Therapeutics Ltd. (CMMB) shares rose over 7% to $3.32 [4]. - Nautilus Biotechnology Inc. (NAUT) shares increased by over 7% to $1.35 [4]. - ProQR Therapeutics N.V. (PRQR) shares were up over 7% at $2.92 [4]. - Tyra Biosciences Inc. (TYRA) shares increased by over 7% to $15.00 [4]. - Imunon Inc. (IMNN) shares rose over 4% to $4.90 [4].

Summary of Chemomab Therapeutics (CMMB) FY Conference Company Overview - **Company**: Chemomab Therapeutics - **Focus**: Development of novel treatments for inflammatory and fibrotic diseases - **Lead Asset**: First-in-class monoclonal antibody targeting CCL24, involved in inflammation and fibrosis [2][4] Industry Context - **Target Disease**: Primary sclerosing cholangitis (PSC) - **Characteristics**: Significant inflammation and fibrosis in the bile duct, no approved treatments available [3][5] - **Patient Demographics**: Approximately 70,000 patients in major markets, primarily young men around their 40s [6] Clinical Development - **Phase II Study**: Successfully completed with positive results - **Participants**: 76 patients, treated with Nebucadnezar at doses of 10 mg/kg, 20 mg/kg, and placebo [9] - **Endpoints**: Safety, tolerability, and various markers of disease progression [10] - **Results**: - Met primary safety endpoint and secondary endpoints showing anti-inflammatory and anti-fibrotic activity [11] - Identified 20 mg/kg as the effective dose for further studies [11] Efficacy and Safety Data - **Biomarker Improvements**: - Significant reduction in liver stiffness and ELF score, indicating disease progression [12][13] - Dose-dependent improvements in inflammatory markers such as IL-6 and IL-18 [14] - **Long-term Safety**: - 93% of eligible patients continued in open-label extension, showing sustained reduction in biomarkers after 48 weeks [16] - Nebucadnezar remained safe and well-tolerated [16] Competitive Landscape - **Unique Positioning**: - Nebucadnezar is the only drug suggesting disease modification in PSC, unlike competitors focusing on symptom management [6][7] - Potential to become the first approved drug for PSC, addressing a significant unmet medical need [8] Market Opportunity - **Commercial Potential**: - Estimated annual commercial opportunity exceeding $1 billion under conservative assumptions [9] - Premium pricing expected due to first-in-class mechanism and significant unmet need [9] Regulatory Engagement - **FDA Interaction**: - Clear alignment with FDA on a single pivotal study for full approval of Nebucadnezar in PSC [20][21] - Study design will evaluate multiple clinical events beyond just liver transplant and death [21] Future Plans - **Phase III Study**: - Preparations underway to initiate Phase III clinical study as soon as possible [22] - Ongoing discussions with potential partners to facilitate market entry [22] Conclusion - **Transformative Potential**: - Nebucadnezar represents a breakthrough in PSC and potentially other fibrotic diseases, with strong data supporting its efficacy [23] - Chemomab Therapeutics is positioned to lead in addressing this rare disease with significant unmet needs [23]

Core Insights - Chemomab Therapeutics Ltd. is a clinical stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases with high unmet need [3] - The company will present at the H.C. Wainwright 27th Annual Global Investment Conference, with a prerecorded presentation available starting September 5, 2025 [1][2] Company Overview - Chemomab is developing nebokitug (CM-101), a first-in-class dual activity monoclonal antibody targeting the soluble protein CCL24, which plays a role in fibrosis and inflammation [3] - Nebokitug has shown disease-modifying potential and a favorable safety profile in clinical and preclinical studies, indicating its potential to treat severe fibro-inflammatory diseases [3] - The company has reported positive results from five clinical trials of nebokitug, particularly from the Phase 2 SPRING trial in primary sclerosing cholangitis (PSC) [3] - Chemomab is preparing for a potential Phase 3 trial in PSC, which will be a single pivotal trial with a clinical event primary endpoint, aiming for full regulatory approval [3] - Nebokitug has received Orphan Drug designation from the FDA and EMA, as well as Fast Track designation from the FDA for the treatment of PSC [3] - The program for treating systemic sclerosis with nebokitug has an open U.S. IND [3]

Core Insights - Catholic Medical Mission Board (CMMB) is launching an emergency response in South Sudan due to a cholera outbreak and a deepening hunger crisis affecting thousands of lives in Upper Nile and Central Equatoria State [1] - The cholera outbreak has infected over 85,700 individuals, primarily children under 14, with case fatality rates exceeding WHO emergency thresholds [1] Group 1: Emergency Response - CMMB is distributing P&G Purifier of Water sachets to families in the most affected areas to curb the cholera spread [2] - The partnership with P&G has been crucial in enabling CMMB to respond quickly to the crisis [2] - Additional resources are urgently needed to address the complex health threats faced by the population [3] Group 2: Collaborative Efforts - CMMB supports a consortium of local and international actors to implement a multisectoral response to the emergency [4] - The organization is involved in supporting oral cholera vaccination campaigns led by the Ministry of Health, with logistical support from UNICEF and WHO [7] - CMMB is running mobile clinics to provide treatment for childhood illnesses and nutrition services for displaced populations [7] Group 3: Call to Action - CMMB has launched an emergency campaign to expand its lifesaving response, emphasizing the urgency of contributions to prevent further deaths [5] - The organization has a long history of providing medical and development aid, focusing on women's and children's health in various countries [6] - In 2024, CMMB's Access to Medicines program delivered $278.9 million worth of medicines and medical supplies to 32 countries [6]

Financial Performance - The company reported a net loss of $5,380,000 for the six months ended June 30, 2025, compared to a net loss of $7,499,000 for the same period in 2024, indicating a reduction in losses of about 28.3%[6] - The net loss for the six months ended June 30, 2025, was $5,380 thousand, compared to a net loss of $7,499 thousand for the same period in 2024, representing a 28.3% improvement[28] - Total operating expenses for the six months ended June 30, 2025, were $5,749,000, down from $7,816,000 in the prior year, reflecting a decrease of approximately 26.5%[6] - Research and development expenses decreased to $3,780,000 for the six months ended June 30, 2025, from $6,080,000 in 2024, a reduction of about 37.8%[6] - General and administrative expenses for the six months ended June 30, 2025, were $1,969 thousand, an increase of 13.4% from $1,736 thousand in 2024[33] Assets and Equity - As of June 30, 2025, total assets decreased to $11,129,000 from $16,964,000 as of December 31, 2024, representing a decline of approximately 34.5%[4] - The company’s total shareholders' equity decreased to $9,699,000 as of June 30, 2025, from $13,537,000 at the end of 2024, a decline of approximately 28.5%[4] Cash Flow and Resources - The company incurred negative cash flows from operating activities of $6,144,000 for the six months ended June 30, 2025, compared to $7,191,000 in the same period of 2024, indicating an improvement of about 14.6%[10] - Cash and cash equivalents, along with restricted cash, totaled $5,596,000 at the end of the period, compared to $5,110,000 at the same time last year, showing an increase of about 9.5%[10] - Current cash resources are projected to be sufficient to meet planned expenditures through the end of June 2026[13] Shareholder Information - The company had a weighted average number of ordinary shares outstanding of 459,829,621 for the six months ended June 30, 2025, up from 285,111,876 in the prior year, representing an increase of approximately 61.1%[6] - The weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders increased to 459,829,621 for the six months ended June 30, 2025, from 285,111,876 in 2024[28] - The total share-based compensation expenses for the six months ended June 30, 2025, were $245 thousand, a decrease of 31% from $355 thousand for the same period in 2024[25] Fundraising Activities - The Company entered into an At the Market Offering Agreement with Roth Capital Partners, allowing the sale of ADSs with an aggregate offering price of up to $2,863,664[23] - From October 30, 2023, to June 30, 2025, the Company issued 3,326,113 ADSs at an average price of approximately $1.18 per ADS, resulting in net proceeds of $3,641 thousand[24] - The Company signed a Sales Agreement in July 2025 for an ATM Offering with potential gross proceeds of up to $7.26 million[34] Product Development Status - The company has no products approved for sale as of June 30, 2025, and will need to raise additional funds to support operations[12]